Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 23, Mizuho reiterated its “Outperform” rating on Harmony and maintained a price target of $48. The reaffirmation followed Harmony’s presentation of preclinical data for BP1.15205 at the SLEEP 2025 conference.
A scientist performing a blood test on a patient using life sciences tools & services.
BP1.15205, an investigational orexin-2 receptor (OX2R) agonist. The data highlighted “significant wake-promoting and cataplexy-suppressing effects” of BP1.15205 in a standard transgenic mouse model of narcolepsy type 1. Specifically, preclinical characterization described BP1.15205 as having “favorable efficacy and safety/tolerability profiles.” Mizuho noted that while this drug candidate is earlier in development compared to some competitors, it “appears to be the most potent orexin candidate based on EC50 measurements.”
Mizuho’s analysis included a comparison between Harmony’s BP1.15205 and TAK-861/oveporexton, which is currently the most advanced orexin in development, with Phase 3 data expected in the summer. The firm concluded that Harmony’s candidate “compares favorably against this competitor.” The research firm expressed optimism that Harmony’s orexin candidate could potentially become a “best-in-class asset” in its category, despite being at an earlier stage of development. Mizuho’s near-term focus remains on the upcoming Phase 3 readout for ZYN-002 in Fragile X Syndrome, which is anticipated in the third quarter of 2025.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage biotech firm making a mark in the cannabis sector through the development of a pharmaceutically manufactured, synthetic CBD gel called ZYN-002. The gel is used for rare neuropsychiatric conditions, such as Fragile X syndrome and 22q11.2 deletion syndrome. It’s also developing a cannabinoid-based drug that is synthesized and formulated as a gel for transdermal delivery.
While we acknowledge the potential of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HRMY and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Successful Spin-Off Companies and Their 2025 Returns and 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying.
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center